This paper discusses the lessons learned by our collaborative, transdisciplinary team while developing a pilot/demonstration educational health campaign geared toward underserved communities in the Columbus, Ohio metropolitan area. The objective of the current study was to determine the feasibility of a campaign to raise awareness of the association between family history and cancer risk and to inform individuals of the availability of Jameslink, an online familial cancer risk assessment tool. The research team included members of The Ohio State University Primary Care Research Institute, which includes a unique combination of expertise in Genetics, Behavioral Science, Social and Health Psychology, Communication, Medicine, and Methodology. The experience of the team in developing university and community partnerships, identifying stakeholders and formulating campaign messages is described. Groups who aided in this process as well as the perspectives they brought to the project are discussed. The lessons learned may be helpful to those developing similar community health projects.

Keywords:
Cancer genetics, Cancer risk, Family history, Public health genetics
1.
American Cancer Society: Cancer facts and figures. Atlanta, American Cancer Society, 2005.
2.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.
3.
American Cancer Society: Ohio cancer facts and figures. Columbus, American Cancer Society, 2006.
4.
Surveillance, epidemiology, and end results program, 1975–2002. Bethesda, Division of Cancer Control and Population Sciences, National Cancer Institute, 2005.
5.
Ramsey SD, Yoon P, Moonesinghe R, Khoury MJ: Population-based study of the prevalence of family history of cancer: implications for cancer screening and prevention. Genet Med 2006;8:571–575.
6.
Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E: Family history and the risk of endometrial cancer. Int J Cancer 1994;59:460–462.
7.
Slattery ML, Kerber RA: A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 1993;270:1563–1568.
8.
Slattery ML, Kerber RA: Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst 1994;86:1618–1626.
9.
Offit K: Clinical Cancer Genetics: Risk Counseling and Management. New York, Wiley-Liss, 1998.
10.
Yoon PW, Scheuner MT, Khoury MJ: Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 2003;24:128–135.
11.
Sweet KM, Bradley TL, Westman JA: Identification and referral of families at high risk for cancer susceptibility. J Clin Oncol 2002;20:528–537.
12.
Acheson LS, Wiesner GL, Zyzanski SJ, Goodwin MA, Stange KC: Family history-taking in community family practice: implications for genetic screening. Genet Med 2000;2:180–185.
13.
Fry A, Campbell H, Gudmunsdottir H, Rush R, Porteous M, Gorman D, Cull A: GPs’ views on their role in cancer genetics services and current practice. Fam Pract 1999;16:468–474.
14.
Hampel H, Sweet K, Westman JA, Offit K, Eng C: Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004;41:81–91.
15.
National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian. NCCN, 2006.
16.
Emmons KM, Wong M, Puleo E, Weinstein N, Fletcher R, Colditz G: Tailored computer-based cancer risk communication: correcting colorectal cancer risk perception. J Health Commun 2004;9:127–141.
17.
Westman J, Hampel H, Bradley T: Efficacy of a touchscreen computer based family cancer history questionnaire and subsequent cancer risk assessment. J Med Genet 2000;37:354–360.
18.
Jameslink: Personalized cancer risk assessment. 2007. http://www.jamesline.com/go/familyhistory.
19.
Wolpert CM: Surgeon General launches new public health campaign: the family history initiative. JAAPA 2005;18:20–22.
20.
Piniewski-Bond J, Celestino PB, Mahoney MC, Farrell CD, Bauer JE, Hastrup JL, Cummings KM: A cancer genetics education campaign: delivering parallel messages to clinicians and the public. J Cancer Educ 2003;18:96–99.
21.
Paskett ED, Tatum CM, D’Agostino R Jr, Rushing J, Velez R, Michielutte R, Dignan M: Community-based interventions to improve breast and cervical cancer screening: results of the Forsyth County Cancer Screening (FoCaS) Project. Cancer Epidemiol Biomarkers Prev 1999;8:453–459.
22.
Cram P, Fendrick AM, Inadomi J, Cowen ME, Carpenter D, Vijan S: The impact of a celebrity promotional campaign on the use of colon cancer screening: the Katie Couric effect. Arch Intern Med 2003;163:1601–1605.
23.
Carney JK, Ewing JF, Finley CA: Progress in breast cancer screening: Vermont’s efforts. J Public Health Manag Pract 1996;2:57–63.
24.
Petrella RJ, Speechley M, Kleinstiver PW, Ruddy T: Impact of a social marketing media campaign on public awareness of hypertension. Am J Hypertens 2005;18:270–275.
25.
Bett N, Aroney G, Thompson P: Impact of a national educational campaign to reduce patient delay in possible heart attack. Aust N Z J Med 1993;23:157–161.
26.
Miles A, Rapoport L, Wardle J, Afuape T, Duman M: Using the mass-media to target obesity: an analysis of the characteristics and reported behaviour change of participants in the BBC’s ‘Fighting Fat, Fighting Fit’ campaign. Health Educ Res 2001;16:357–372.
27.
Silver FL, Rubini F, Black D, Hodgson CS: Advertising strategies to increase public knowledge of the warning signs of stroke. Stroke 2003;34:1965–1968.
28.
Reger B, Wootan MG, Booth-Butterfield S: A comparison of different approaches to promote community-wide dietary change. Am J Prev Med 2000;18:271–275.
29.
Randolph W, Viswanath K: Lessons learned from public health mass media campaigns: marketing health in a crowded media world. Annu Rev Public Health 2004;25:419–437.
30.
Leventhal H: Findings and theory in the study of fear communications; in Berkowitz L (ed): Advances in Experimental Psychology, vol 5. New York, Academic Press, 1970, pp 119–186.
31.
Leventhal H, Benyamini Y, Brownlee S, Diefenbach M, Leventhal E, Patrick-Miller L, Robitaille C: Ilness representations: theoretical foundations; in Weinman JA, Petrie KJ (eds): Perceptions of Health and Illness. Australia, Harwood Academic Publishers, 1997, pp 19–46.
32.
Baumann LJ, Zimmerman RS, Leventhal H: An experiment in common sense: education at blood pressure screening. Patient Educ Couns 1989;14:53–67.
33.
Leventhal H, Watts JC: Sources of resistance to fear-arousing communications on smoking and lung cancer. J Pers 1966;34:155–175.
34.
US Census Bureau: State and County QuickFacts. 2007. http://quickfacts.census.gov/qfd/ states/39/39049.html.
35.
Hall MJ, Olopade OI: Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006;24:2197–2203.
36.
Columbus Neighborhood Health Center, Inc. http://www.colnhc.org/.
37.
Primary Care Research Institute, The Ohio State University. http://medicine.osu.edu/pcri/.
38.
The Diversity Enhancement Program at the James Cancer Hospital and Solove Research Institute. 2007. http://www.jamesline.com/patientsandvisitors/support/diversity/.
39.
African American and African Studies Community Extension Center. 2007. http://aaascec.osu.edu/.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.